{"createdAt":"8/2/2020, 1:16:47 PM","timestamp":1596388607921,"Company ID number":"110","DMX_ISSUER_NAME":"Beijing SL Pharmaceutical Co., Ltd.","DMX_ISSUER_ID":"IID000000002148569","Country of Classification":"CHINA","name":"Beijing SL Pharmaceutical Co Ltd ","code":"002038","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"北京双鹭药业股份有限公司_徐明波","group":"board","name":"徐明波","title":"董事长,董事","isMale":true,"age":"56","degree":"博士","salary":"38.50万","stockAmount":"2.32亿","description":"徐明波,男,出生于1964年3月,中国国籍,无境外永久居留权,毕业于中国人民解放军军事医学科学院分子生物学专业,博士研究生学历,教授职称。1986年8月至1994年11月就职于军事医学科学院,任课题组组长;1994年12月至今就职于北京双鹭药业股份有限公司,任董事长、总经理;2003年10月至今就职于北京双鹭立生医药科技有限公司,任董事长;2009年6月至今就职于新乡双鹭药业有限公司,任董事长;2008年5月至今就职于PNUVAXSLBIOPHARMACEUTICALSINC,任董事长;2011年1月至今就职于北京双鹭生物技术有限公司,任董事长;2009年3月至2016年6月,就职于辽宁迈迪生物科技有限公司,任董事;2016年6月至今任股份公司董事,任期三年。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_梁淑洁","group":"board","name":"梁淑洁","title":"董事","isMale":false,"age":"54","degree":"本科","salary":"26.00万","stockAmount":"210.1万","description":"梁淑洁女士,1966年出生,大学学历,毕业于西安政治学院,先后在济南军区、军事医学科学院毒物药物研究所从事宣传和干部管理工作。2002年2月到北京双鹭药业股份有限公司工作,2002年5月起任办公室主任,2003年6月被聘为董事会秘书,2010年荣获第13届中国上市公司“最佳董秘奖”,第四届、第五届、第六届董事会董事,现兼任北京星昊医药股份有限公司、长风药业股份有限公司、天津时代怡诺科技股份有限公司、北京崇德英盛创业投资有限公司、上海信忠医药科技有限公司董事。现被提名为公司第七届董事会董事候选人。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_陈玉林","group":"board","name":"陈玉林","title":"董事","isMale":true,"age":"75","degree":"本科","salary":"5.000万","stockAmount":"-","description":"陈玉林先生,1945年生,大学学历,教授级高级工程师,享受政府特殊津贴,全国劳动模范,“五一劳动奖章”获得者。1970年毕业于中国纺织大学。历任新乡化学纤维厂车间技术员、副主任、主任,厂党委副书记、工会主席,新乡化学纤维厂及新乡白鹭化纤集团有限责任公司党委书记、厂长、董事长、总经理。公司第一届、二届、三届、四届、五届、六届董事会董事,1994年12月至2004年3月任北京双鹭药业股份有限公司董事长。现被提名为公司第七届董事会董事候选人。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_王文新","group":"board","name":"王文新","title":"董事","isMale":true,"age":"54","degree":"硕士","salary":"0.00","stockAmount":"-","description":"王文新先生,1966年出生,经济学硕士,高级经济师、会计师。新乡化纤股份有限公司董事、副总经理、董事会秘书、财务负责人,现任新乡化纤股份有限公司董事,集团公司总经理,民生证券有限责任公司监事,北京双鹭药业股份有限公司董事,新乡市飞鹭纺织科技有限公司副董事长。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_苏志国","group":"board","name":"苏志国","title":"独立董事","isMale":true,"age":"66","degree":"博士","salary":"5.000万","stockAmount":"-","description":"苏志国,现任北京神州细胞生物技术集团股份公司独立董事,1954年出生,中国国籍,无境外永久居留权,博士,1985年12月毕业于英国曼彻斯特大学,获博士学位。1986年1月至1987年1月任荷兰德尔夫特大学博士后科研工作;1987年2月至1997年11月历任大连理工大学讲师、副教授、教授;1997年11月至今任中国科学院过程工程研究所生化工程国家重点实验室研究员。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_魏素艳","group":"board","name":"魏素艳","title":"独立董事","isMale":false,"age":"68","degree":"硕士","salary":"5.000万","stockAmount":"2250","description":"魏素艳女士,1952年生,经济学学士,管理学硕士,教授,中国注册会计师,中国注册资产评估师。历任北京理工大学管理与经济学院会计系教师。现任北京理工大学管理与经济学院会计学教授、硕士生导师、会计系责任教授,兼任北京瑞风协同科技股份有限公司和华夏电子通讯股份公司独立董事。主持和参与完成较大项目和科研课题10余项,主持的课题“北京理工大学会计专业实践教学环节的改革”,获2001年北京市优秀教学成果二等奖。2003年6月至2009年4月任北京双鹭药业股份有限公司独立董事。现任北京双鹭药业股份有限公司第六届董事会独立董事。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_齐燕明","group":"supervisoryCommittee","name":"齐燕明","title":"监事会主席","isMale":false,"age":"50","degree":"本科","salary":"21.00万","stockAmount":"3000","description":"齐燕明女士,1970年生,大学学历,教授级高级工程师,1993年毕业于中国药科大学,先后在北京第三制药厂、美国泛华医药公司工作,2003年1月到北京双鹭药业股份有限公司工作,历任技术员、质量监督员、QA主管,2006年1月起任北京双鹭药业股份有限公司质量保证部主任。北京双鹭药业股份有限公司第五届监事会监事,第六届监事会主席,未在其他企业兼职。现被提名为北京双鹭药业股份有限公司第七届监事会监事。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_张春雷","group":"supervisoryCommittee","name":"张春雷","title":"监事","isMale":true,"age":"57","degree":"大专","salary":"0.00","stockAmount":"-","description":"张春雷先生,1963年出生,大专学历,高级工程师,曾任集团公司董事、公司副总经理,现任新乡化纤股份有限公司监事会主席,控股股东白鹭集团董事、党委副书记、纪委书记,兼任北京双鹭药业股份有限公司监事。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_杨仲璠","group":"supervisoryCommittee","name":"杨仲璠","title":"职工监事","isMale":false,"age":"51","degree":"硕士","salary":"18.00万","stockAmount":"5310","description":"杨仲璠女士,1969年生,硕士,研究员,历任卫生部兰州生物制品研究所助理工程师、工程师,曾获国家科学技术进步二等奖一项,甘肃省科学技术进步一等奖二项。2003年8月到北京双鹭药业股份有限公司工作,最近五年任北京双鹭药业股份有限公司技术中心主任助理、项目管理部主任。作为职工代表出任北京双鹭药业股份有限公司第三届、第四届、第五届监事。第六届监事会监事。未在其他企业兼职。","lastUpdated":"2018-03-20"},{"id":"北京双鹭药业股份有限公司_徐明波","group":"manager","name":"徐明波","title":"总经理","isMale":true,"age":"56","degree":"博士","salary":"38.50万","stockAmount":"2.32亿","description":"徐明波,男,出生于1964年3月,中国国籍,无境外永久居留权,毕业于中国人民解放军军事医学科学院分子生物学专业,博士研究生学历,教授职称。1986年8月至1994年11月就职于军事医学科学院,任课题组组长;1994年12月至今就职于北京双鹭药业股份有限公司,任董事长、总经理;2003年10月至今就职于北京双鹭立生医药科技有限公司,任董事长;2009年6月至今就职于新乡双鹭药业有限公司,任董事长;2008年5月至今就职于PNUVAXSLBIOPHARMACEUTICALSINC,任董事长;2011年1月至今就职于北京双鹭生物技术有限公司,任董事长;2009年3月至2016年6月,就职于辽宁迈迪生物科技有限公司,任董事;2016年6月至今任股份公司董事,任期三年。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_梁淑洁","group":"manager","name":"梁淑洁","title":"董事会秘书","isMale":false,"age":"54","degree":"本科","salary":"26.00万","stockAmount":"210.1万","description":"梁淑洁女士,1966年出生,大学学历,毕业于西安政治学院,先后在济南军区、军事医学科学院毒物药物研究所从事宣传和干部管理工作。2002年2月到北京双鹭药业股份有限公司工作,2002年5月起任办公室主任,2003年6月被聘为董事会秘书,2010年荣获第13届中国上市公司“最佳董秘奖”,第四届、第五届、第六届董事会董事,现兼任北京星昊医药股份有限公司、长风药业股份有限公司、天津时代怡诺科技股份有限公司、北京崇德英盛创业投资有限公司、上海信忠医药科技有限公司董事。现被提名为公司第七届董事会董事候选人。","lastUpdated":"2018-04-11"},{"id":"北京双鹭药业股份有限公司_李亚军","group":"manager","name":"李亚军","title":"常务副总经理,财务负责人","isMale":true,"age":"43","degree":"本科","salary":"22.00万","stockAmount":"3.043万","description":"李亚军先生,1977年出生,大学学历,副研究员。2000年毕业于天津商学院,同年到北京双鹭药业股份有限公司工作,历任技术中心技术员、课题负责人、生产部车间主任。现任北京双鹭药业股份有限公司生产部主任。2012年5月23日被聘为北京双鹭药业股份有限公司副总经理。","lastUpdated":"2018-04-11"}],"companyName":"北京双鹭药业股份有限公司","province":"北京市","englishName":"Beijing SL Pharmaceutical Co Ltd","industry":"医药生物 — 生物制品Ⅱ","website":"www.slpharm.com.cn","mainBusiness":"基因工程及相关药物的研究开发和生产经营","productsName":["生物","生化药","化学药"],"actualController":"徐明波","actualControllerSharePercentage":"22.58%","registeredCapital":"10.27亿元","employeeAmount":"730","phone":"86-010-88627635","location":"北京市海淀区阜石路69号碧桐园一号楼","chineseDescription":"北京双鹭药业股份有限公司主要专注于基因工程及相关药物的研究开发和生产经营,紧紧围绕疾病谱的变化布局研发和生产。主要产品包括重组人粒细胞刺激因子、重组人白介素-2、重组人白介素-11、重组人碱性成纤维细胞生长因子、替莫唑胺、三氧化二砷、来那度胺、复合辅酶、胸腺五肽、依诺肝素钠、氯雷他定分散片、替米沙坦、多西他赛、阿德福韦酯、杏灵滴丸等,涉及肿瘤、肝病、心脑血管、肾病等领域。公司入选国家火炬计划重点高新技术企业、中关村科技园海淀园首批“百家创新企业”、“北京生物医药产业跨越发展工程”(G20工程)和中关村国家自主创新示范区首批“十百千工程”重点培育企业。2010-2011连续两年被评为最具竞争力的...查看全部▼北京双鹭药业股份有限公司主要专注于基因工程及相关药物的研究开发和生产经营,紧紧围绕疾病谱的变化布局研发和生产。主要产品包括重组人粒细胞刺激因子、重组人白介素-2、重组人白介素-11、重组人碱性成纤维细胞生长因子、替莫唑胺、三氧化二砷、来那度胺、复合辅酶、胸腺五肽、依诺肝素钠、氯雷他定分散片、替米沙坦、多西他赛、阿德福韦酯、杏灵滴丸等,涉及肿瘤、肝病、心脑血管、肾病等领域。公司入选国家火炬计划重点高新技术企业、中关村科技园海淀园首批“百家创新企业”、“北京生物医药产业跨越发展工程”(G20工程)和中关村国家自主创新示范区首批“十百千工程”重点培育企业。2010-2011连续两年被评为最具竞争力的医药上市企业前五名,近几年综合实力迅速提升并已成为国内生物制药的骨干企业。收起▲","foundedDate":"1994-12-24","goPublicDate":"2004-09-09","companyHistory":"北京双鹭药业股份有限公司（以下简称“公司”或“本公司”）是由新乡白鹭化纤集团有限责任公司等四家法人单位以及徐明波等五位自然人于2000年6月共同发起设立的股份有限公司。经中国证券监督管理委员会批准，公司以募集方式向社会公开发行A股股票并于2004年9月9日在深圳证券交易所上市。\n　　截止2019年12月31日,本公司累计发行股本总数102,735.00万股,注册资本为102,735.00万元。公司的企业法人营业执照注册号：91110000102299779W，注册地址：北京海淀区西三环北路100号金玉大厦1103-1105室，总部地址：北京市海淀区阜石路69号碧桐园一号楼，法定代表人为徐明波。收起▲","shareholders":[{"organizationId":"","holderName":"徐明波","totalShare":"2.32亿","sharePercentage":"22.58%"},{"organizationId":"00004114","holderName":"新乡白鹭投资集团有限公司","totalShare":"2.12亿","sharePercentage":"20.63%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"1236.93万","sharePercentage":"1.20%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1203.62万","sharePercentage":"1.17%"},{"organizationId":"","holderName":"金燕","totalShare":"1062.11万","sharePercentage":"1.03%"},{"organizationId":"","holderName":"汪滨","totalShare":"761.39万","sharePercentage":"0.74%"},{"organizationId":"","holderName":"中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金","totalShare":"607.76万","sharePercentage":"0.59%"},{"organizationId":"","holderName":"华夏基金-农业银行-华夏中证金融资产管理计划","totalShare":"587.66万","sharePercentage":"0.57%"},{"organizationId":"","holderName":"中欧基金-农业银行-中欧中证金融资产管理计划","totalShare":"580.89万","sharePercentage":"0.57%"},{"organizationId":"","holderName":"中国银河证券股份有限公司约定购回专用账户","totalShare":"575.99万","sharePercentage":"0.56%"}],"englishDescription":"Beijing SL Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of genetic engineering and related drugs. The Company's main products include complex coenzyme, arsenic trioxide, recombinant human granulocyte stimulating factor, recombinant human interleukin-2, recombinant human basic fibroblast growth factor, thymopentin, enoxaparin and Xingling dropping pills, among others. The Company distributes its products in domestic market and to overseas markets.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"41.29","Price to sales (ttm)":"8.17","Price to book (mrq)":"2.92","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"0.11","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"7.02","Return on equity (ttm)":"6.50","Income statement":{"Revenue":"2,029.70","Total revenue":"2,029.70","Cost of revenue, total":"417.38","Gross profit":"1,612.32","Selling/general/admin. expenses, total":"972.03","Research & development":"122.25","Depreciation/amortization":"58.78","Interest exp.(inc.),net-operating, total":"(72.46)","Unusual expense (income)":"0.03","Other operating expenses, total":"(29.21)","Total operating expense":"1,468.80","Operating income":"560.90","Other, net":"(0.01)","Net income before taxes":"560.89","Provision for income taxes":"81.39","Net income after taxes":"479.50","Minority interest":"7.29","Net income before extra. items":"486.78","Net income":"486.78","Income available to com excl extraord":"486.78","Income available to com incl extraord":"486.78","Diluted net income":"486.78","Diluted weighted average shares":"1,027.35","Diluted eps excluding extraord items":"0.47","Dps - common stock primary issue":"0.20","Diluted normalized eps":"0.47","Gain (loss) on sale of assets":"(0.03)"},"Balance sheet":{"Cash":"0.09","Cash & equivalents":"1,260.77","Short term investments":"653.25","Cash and short term investments":"1,914.11","Accounts receivable - trade, net":"603.84","Total receivables, net":"645.34","Total inventory":"108.35","Prepaid expenses":"197.19","Other current assets, total":"0.35","Total current assets":"2,865.34","Property/plant/equipment, total - gross":"919.33","Accumulated depreciation, total":"(279.18)","Property/plant/equipment, total - net":"640.15","Intangibles, net":"641.18","Long term investments":"606.08","Note receivable - long term":"6.15","Other long term assets, total":"466.07","Total assets":"5,224.97","Accounts payable":"178.51","Accrued expenses":"29.72","Notes payable/short term debt":"24.51","Other current liabilities, total":"99.90","Total current liabilities":"332.63","Long term debt":"0.00","Total long term debt":"0.00","Total debt":"24.51","Deferred income tax":"5.86","Minority interest":"13.01","Other liabilities, total":"65.26","Total liabilities":"416.77","Common stock, total":"1,027.35","Additional paid-in capital":"7.47","Retained earnings (accumulated deficit)":"3,782.11","Other equity, total":"(8.73)","Total equity":"4,808.20","Total liabilities & shareholders' equity":"5,224.97","Total common shares outstanding":"1,027.35","Tangible book value per share, common eq":"4.06","Treasury stock - common":"(9.47)"},"Cash flow":{"Cash receipts":"2,285.45","Cash payments":"(288.88)","Cash taxes paid":"(291.85)","Changes in working capital":"(1,038.89)","Cash from operating activities":"665.83","Capital expenditures":"(272.78)","Other investing cash flow items, total":"(110.39)","Cash from investing activities":"(383.18)","Financing cash flow items":"2.68","Total cash dividends paid":"(205.56)","Issuance (retirement) of debt, net":"3.93","Cash from financing activities":"(198.95)","Foreign exchange effects":"0.21","Net change in cash":"83.91"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"13.98","52 Week High":"15.97","52 Week Low":"10.83","Pricing date":"","10 Day Average Trading Volume":"23.25","Market Capitalization":"14,362.35","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"306.02","Beta":"0.85","1 Day Price Change":"1.45","13 Week Price Return (Daily)":"25.49","26 Week Price Return (Daily)":"-1.55","5 Day Price Return (Daily)":"8.96","52 Week Price Return (Daily)":"0.14","Year To Date Price Return (Daily)":"6.31","Month to Date Price Return (Daily)":"9.13","Price Relative to S&P500 (4 Week)":"0.04","Price Relative to S&P500 (13 Week)":"-1.34","Price Relative to S&P500 (26 Week)":"-22.89","Price Relative to S&P500 (52 Week)":"-31.94","Price Relative to S&P500 (YTD)":"-18.69"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.47","EPS excl. Extra Items (TTM)":"0.34","EPS Normalized (Annual)":"0.47","Revenue per Share (Annual)":"1.98","Revenue per Share (TTM)":"1.71","Book Value (Per Share Annual)":"4.68","Book Value (Per Share Quarterly)":"4.79","Tangible Book Value (Per Share Annual)":"4.06","Tangible Book Value (Per Share Quarterly)":"4.17","Cash Per Share (Per Share Annual)":"1.86","Cash Per Share (Per Share Quarterly)":"0.92","Cash Flow (Per Share Annual)":"0.54","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.20","Dividends (Per Share TTM)":"0.20","EBITD (Per Share TTM)":"0.34","EPS Basic excl. Extra Items (Annual)":"0.47","EPS Basic excl. Extra Items (TTM)":"0.34","EPS incl. Extra Items (Annual)":"0.47","EPS incl. Extra Items (TTM)":"0.34","Free Cash Flow (Per Share TTM)":"0.31","Dividend (Per Share 5Y)":"0.20"},"Valuation":{"P/E excl. Extra Items (Annual)":"29.50","P/E excl. Extra Items (TTM)":"41.29","P/E Normalized (Annual)":"29.50","Price to sales (Annual)":"7.08","Price to sales (TTM)":"8.17","Price to Tangible Book (Annual)":"3.45","Price to Tangible Book (Quarterly)":"3.35","Price to Free Cash Flow (Per Share Annual)":"76.60","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"44.51","Price to Book (Annual)":"2.99","Price to Book (Quarterly)":"2.92","P/E Basic excl. Extra Items (TTM)":"35.30","P/E excl. Extra Items High (TTM)":"54.33","P/E excl. Extra Items Low (TTM)":"23.63","P/E incl. Extra Items (TTM)":"41.29","Net Debt (Interim)":"-941.45","Net Debt (Annual)":"-1,889.60","Dividend Yield (5Y)":"1.11","Dividend Yield":"1.43","Current Dividend Yield (TTM)":"1.43"},"Financial Strength":{"Free Cash Flow (Annual)":"187.49","Current Ratio (Annual)":"8.61","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"42.21","Quick Ratio (Annual)":"8.29","Total Debt/Total Equity (Annual)":"0.51","Current EV/Free Cash Flow (Annual)":"162.46","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"7.92","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"7.40","Total Debt/Total Equity (Quarterly)":"0.11","Free Cash Flow (TTM)":"322.65","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"59.08"},"Margins":{"Gross Margin (Annual)":"79.44","Gross Margin (TTM)":"77.88","Net Profit Margin % (Annual)":"23.62","Net Profit Margin (TTM)":"19.41","Operating Margin (Annual)":"27.63","Operating Margin (TTM)":"22.88","Pretax Margin (TTM)":"22.88","Pretax Margin (Annual)":"27.63","Operating Margin (5Y)":"39.81","Pretax Margin (5Y)":"40.12","Free Operating Cash Flow/Revenue (5Y)":"5.96","Free Operating Cash Flow/Revenue (TTM)":"18.35","Gross Margin (5Y)":"74.03","Net Profit Margin (5Y)":"34.14"},"Management Effectiveness":{"Return on Assets (Annual)":"9.39","Return on Equity (TTM)":"6.50","Return on Average Equity (Annual)":"10.46","Return on Average equity (TTM)":"7.22","Return on Investment (Annual)":"10.20","Return on Investment (TTM)":"7.02","Return on Average Assets (5Y)":"11.97","Return on Average Equity (5Y)":"12.95","Return on Investment (5Y)":"12.72","Asset Turnover (Annual)":"0.40","Asset Turnover (TTM)":"0.34","Inventory Turnover (Annual)":"2.32","Inventory Turnover (TTM)":"2.03","Net Income/Employee (Annual)":"691,417.80","Net Income/Employee (TTM)":"467,526.60","Receivables Turnover (Annual)":"3.18","Receivables Turnover (TTM)":"2.86","Revenue/Employee (Annual)":"2,926,754.00","Revenue/Employee (TTM)":"2,409,236.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-58.19","Revenue Growth Rate (5Y)":"10.31","EPS Growth (Quarterly YoY)":"-69.30","EPS Growth (TTM YoY)":"-41.02","EPS Growth Rate (5Y)":"-7.26","Dividend Growth Rate (3Y)":"14.47","Revenue Growth (TTM YoY)":"-19.80","Revenue Growth (Per Share 5Y)":"9.86","Revenue Growth Rate (3Y)":"26.20","EPS Growth Rate (3Y)":"2.49","Book Value Growth Rate (Per Share 5Y)":"8.40","Tangible Book Value Total Equity CAGR (5Y)":"7.16","Capital Spending growth rate 5 year":"12.55","EBITDA CAGR (5Y)":"-5.33","EBITDA Interim CAGR (5Y)":"-13.67","Free Operating Cash Flow CAGR (5Y)":"-3.38","Total Debt CAGR (5Y)":"--","Net Profit Margin Growth Rate (5Y)":"-15.97"},"Income Statement":{"Revenue (Annual)":"2,029.70","Revenue (TTM)":"1,758.74","EBITD (Annual)":"564.17","EBITD (TTM)":"345.67","Earnings Before Taxes (Annual)":"560.89","Earnings Before Taxes (TTM)":"402.33","Net Income to Common (Annual)":"486.78","Net Income to Common (TTM)":"347.81","Earnings Before Taxes Normalized (Annual)":"560.92","Net Income Available to Common Normalized (Annual)":"486.81","Diluted Normalized EPS excl. Extra Items (TTM)":"0.33"}}}